Mineralocorticoid receptor antagonists eplerenone and spironolactone modify adrenal cortex morphology and physiology

Detalhes bibliográficos
Autor(a) principal: Pereira, SS
Data de Publicação: 2021
Outros Autores: Carvalho, LS, Costa, MM, Melo, A, Ferreira, IMPLVO, Gomez-Sanchez, CE, Monteiro, MP, Vinson, G, Pignatelli, D
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://hdl.handle.net/10216/152489
Resumo: Mineralocorticoid receptor antagonists (MRAs) are a class of anti-hypertensive drugs that act by blocking aldosterone action. The aim of this study was to evaluate whether the MRAs spironolactone and eplerenone influence adrenal cortical physiology and morphology. Spontaneous hypertensive rats (SHR, n = 18) and normotensive rats (WKY, n = 18) were randomly exposed to a daily dose of spironolactone (n = 6), eplerenone (n = 6), or no drug (n = 6) over 28 days. After that, aldosterone, corticosterone, and 11-deoxycorticosterone plasma concentrations were quantified. Adrenal glands were subjected to morphological analysis to assess lipid droplets content, capsular width, cell proliferation, and steroidogenic proteins expression. The adrenal cortex in untreated SHR showed higher lipid droplet content as than in WKY. In SHR, MRA treatment was associated with higher circulating aldosterone levels and Ki-67 expression in aldosterone-secreting cells. In WKY, the only difference observed after MRA spironolactone treatment was a narrower capsule. There was no difference in abundance of steroidogenic enzyme between groups. In conclusion, MRAs modify adrenal gland function and morphology in SHR. The effects observed within the adrenal glomerulosa with aldosterone-secreting cell proliferation and higher circulating aldosterone levels suggests that MRA treatment provokes activation of the renin angiotensin system. The prognostic value of hyperaldosteronism secondary to MRAs blockade requires further investigation.
id RCAP_a1cec359f86f83ef62aec10727d02c25
oai_identifier_str oai:repositorio-aberto.up.pt:10216/152489
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Mineralocorticoid receptor antagonists eplerenone and spironolactone modify adrenal cortex morphology and physiologyAdrenal cortexEplerenoneMineralocorticoid receptor antagonistsSpironolactoneSteroidsMineralocorticoid receptor antagonists (MRAs) are a class of anti-hypertensive drugs that act by blocking aldosterone action. The aim of this study was to evaluate whether the MRAs spironolactone and eplerenone influence adrenal cortical physiology and morphology. Spontaneous hypertensive rats (SHR, n = 18) and normotensive rats (WKY, n = 18) were randomly exposed to a daily dose of spironolactone (n = 6), eplerenone (n = 6), or no drug (n = 6) over 28 days. After that, aldosterone, corticosterone, and 11-deoxycorticosterone plasma concentrations were quantified. Adrenal glands were subjected to morphological analysis to assess lipid droplets content, capsular width, cell proliferation, and steroidogenic proteins expression. The adrenal cortex in untreated SHR showed higher lipid droplet content as than in WKY. In SHR, MRA treatment was associated with higher circulating aldosterone levels and Ki-67 expression in aldosterone-secreting cells. In WKY, the only difference observed after MRA spironolactone treatment was a narrower capsule. There was no difference in abundance of steroidogenic enzyme between groups. In conclusion, MRAs modify adrenal gland function and morphology in SHR. The effects observed within the adrenal glomerulosa with aldosterone-secreting cell proliferation and higher circulating aldosterone levels suggests that MRA treatment provokes activation of the renin angiotensin system. The prognostic value of hyperaldosteronism secondary to MRAs blockade requires further investigation.MDPI20212021-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10216/152489eng2227-905910.3390/biomedicines9040441Pereira, SSCarvalho, LSCosta, MMMelo, AFerreira, IMPLVOGomez-Sanchez, CEMonteiro, MPVinson, GPignatelli, Dinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-29T15:21:34Zoai:repositorio-aberto.up.pt:10216/152489Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T00:21:37.242097Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Mineralocorticoid receptor antagonists eplerenone and spironolactone modify adrenal cortex morphology and physiology
title Mineralocorticoid receptor antagonists eplerenone and spironolactone modify adrenal cortex morphology and physiology
spellingShingle Mineralocorticoid receptor antagonists eplerenone and spironolactone modify adrenal cortex morphology and physiology
Pereira, SS
Adrenal cortex
Eplerenone
Mineralocorticoid receptor antagonists
Spironolactone
Steroids
title_short Mineralocorticoid receptor antagonists eplerenone and spironolactone modify adrenal cortex morphology and physiology
title_full Mineralocorticoid receptor antagonists eplerenone and spironolactone modify adrenal cortex morphology and physiology
title_fullStr Mineralocorticoid receptor antagonists eplerenone and spironolactone modify adrenal cortex morphology and physiology
title_full_unstemmed Mineralocorticoid receptor antagonists eplerenone and spironolactone modify adrenal cortex morphology and physiology
title_sort Mineralocorticoid receptor antagonists eplerenone and spironolactone modify adrenal cortex morphology and physiology
author Pereira, SS
author_facet Pereira, SS
Carvalho, LS
Costa, MM
Melo, A
Ferreira, IMPLVO
Gomez-Sanchez, CE
Monteiro, MP
Vinson, G
Pignatelli, D
author_role author
author2 Carvalho, LS
Costa, MM
Melo, A
Ferreira, IMPLVO
Gomez-Sanchez, CE
Monteiro, MP
Vinson, G
Pignatelli, D
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Pereira, SS
Carvalho, LS
Costa, MM
Melo, A
Ferreira, IMPLVO
Gomez-Sanchez, CE
Monteiro, MP
Vinson, G
Pignatelli, D
dc.subject.por.fl_str_mv Adrenal cortex
Eplerenone
Mineralocorticoid receptor antagonists
Spironolactone
Steroids
topic Adrenal cortex
Eplerenone
Mineralocorticoid receptor antagonists
Spironolactone
Steroids
description Mineralocorticoid receptor antagonists (MRAs) are a class of anti-hypertensive drugs that act by blocking aldosterone action. The aim of this study was to evaluate whether the MRAs spironolactone and eplerenone influence adrenal cortical physiology and morphology. Spontaneous hypertensive rats (SHR, n = 18) and normotensive rats (WKY, n = 18) were randomly exposed to a daily dose of spironolactone (n = 6), eplerenone (n = 6), or no drug (n = 6) over 28 days. After that, aldosterone, corticosterone, and 11-deoxycorticosterone plasma concentrations were quantified. Adrenal glands were subjected to morphological analysis to assess lipid droplets content, capsular width, cell proliferation, and steroidogenic proteins expression. The adrenal cortex in untreated SHR showed higher lipid droplet content as than in WKY. In SHR, MRA treatment was associated with higher circulating aldosterone levels and Ki-67 expression in aldosterone-secreting cells. In WKY, the only difference observed after MRA spironolactone treatment was a narrower capsule. There was no difference in abundance of steroidogenic enzyme between groups. In conclusion, MRAs modify adrenal gland function and morphology in SHR. The effects observed within the adrenal glomerulosa with aldosterone-secreting cell proliferation and higher circulating aldosterone levels suggests that MRA treatment provokes activation of the renin angiotensin system. The prognostic value of hyperaldosteronism secondary to MRAs blockade requires further investigation.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/10216/152489
url https://hdl.handle.net/10216/152489
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2227-9059
10.3390/biomedicines9040441
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799136132464640000